STAA

STAAR Surgical Company - 10-Q Summary

Business Context and Reporting Period

Company: STAAR Surgical Company (STAAR)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 2, 2010
Business Overview: STAAR designs, develops, manufactures, and sells implantable lenses for cataract surgery (IOLs) and refractive surgery (ICLs). The company operates globally with manufacturing sites in the U.S., Japan, and Switzerland.

Key Financial Metrics

Note: Net Income includes a $4.1 million gain from discontinued operations (sale of Domilens). Loss from continuing operations was $(636) thousand.

Material Changes vs. Prior Period

• Divestiture of Domilens: On March 2, 2010, STAAR sold its German distribution subsidiary, Domilens GmbH, for net cash proceeds of approximately $11.8 million. This transaction generated a $4.1 million net gain, recorded as discontinued operations.
• Revenue Growth: Net sales increased 13.3% year-over-year, driven by a 23% increase in international sales (particularly ICLs and IOLs), partially offset by a 4% decline in U.S. sales.
• Profitability: The company achieved operating income of $76,000 from continuing operations, the first quarterly operating profit since Q3 2000. Gross margin improved to 64.1% due to the expiration of a royalty agreement and the removal of lower-margin third-party products from the Domilens divestiture.
• Litigation Settlement: On March 30, 2010, STAAR settled the Parallax and Moody lawsuits. The company agreed to pay $4.0 million from a restricted court deposit, resolving judgments totaling over $11 million. This settlement returned the interest rate on the Broadwood Note to 7% from a default rate of 20%.
• Cash Flow: Net cash used in operating activities was $1.4 million, compared to $0.4 million in the prior year. However, investing activities provided $11.8 million due to the Domilens sale.

Guidance, Outlook, and Risks

• Strategic Goals: Management aims to achieve net income for the full year 2010, improve gross margins to the mid-60% level, and generate double-digit growth in core ICL and IOL sales.
• Preferred Stock Call: On April 23, 2010, STAAR called all 1.7 million shares of Series A Redeemable Convertible Preferred Stock for redemption at $4.00 per share ($6.8 million total) on May 24, 2010. Holders may convert to common stock at a 1:1 ratio until May 17, 2010. Management expects conversion rather than cash redemption given the stock price exceeds $4.00.
• Debt Obligations: A $5 million Broadwood Promissory Note matures on December 14, 2010. Management intends to repay this from working capital.
• Regulatory Risks: STAAR is awaiting FDA approval for the Visian Toric ICL (TICL) in the U.S. and Japan. The company received a deficiency letter from the FDA in February 2010 regarding the TICL application.
• Market Risks: U.S. ICL sales growth is constrained by the economic recession and the elective nature of refractive surgery. U.S. IOL sales continue to face competition and pricing pressure.

Investor Verification Checklist

• Continuing Operations Profitability: Verify if the company can sustain operating income without the one-time gain from the Domilens sale.
• Preferred Stock Conversion: Monitor the conversion rate of the Series A Preferred Stock to determine if the $6.8 million cash outflow will be required.
• Litigation Cash Impact: Confirm the timing of the $4.0 million settlement payment (expected Q2 2010) and the return of the $3.4 million residual restricted cash.
• U.S. Market Trends: Assess the impact of the economic recovery on elective refractive surgery volumes and the success of new product introductions (nanoFLEX IOL, nanoPOINT injector).
• Debt Repayment: Evaluate the company's ability to repay the $5 million Broadwood Note due in December 2010 using operating cash flows.